ArticleGland surgery2025
Advanced Masaoka-Koga stage as an independent predictor of thymoma recurrence after complete resection: myasthenia gravis was not an independent factor.
Article in Gland surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Preoperative Myasthenia Gravis and Five-Year Outcomes After Thymoma Resection: A Multicenter Cohort Study.Annals of surgical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although myasthenia gravis (MG) commonly coexists with thymoma, its prognostic role in thymoma recurrence is controversial. Therefore, we aimed to identify clinical and pathological predictors of recurrence after thymectomy in a single-center cohort. Methods: We retrospectively reviewed adult patients who underwent thymectomy for pathologically confirmed thymoma between January 2000 and December 2023 at a single tertiary center. Patients with at least 12 months of follow-up were included. Clinical, surgical, and pathological features were compared between patients with and without MG. Survival outcomes, including recurrence-free survival (RFS, R0 subgroup), progression-free survival (PFS, overall cohort), and overall survival (OS), were analyzed using Kaplan-Meier methods with log-rank tests. Independent predictors of recurrence were evaluated using Cox proportional hazards regression restricted to patients with R0 resection. Results: Patients with MG were significantly younger and more likely to undergo transsternal extended thymectomy than those without MG. Although thymoma recurrence was more frequent in the MG group, MG status was not significantly associated with RFS or OS. Kaplan-Meier analysis showed that advanced-stage thymoma (stage III-IV) was associated with significantly shorter RFS, PFS, and OS compared with early-stage disease. In multivariate Cox regression restricted to R0 resections, advanced Masaoka stage remained an independent predictor of recurrence, while tumor size showed only a borderline association. Conclusions: Advanced Masaoka stage is the strongest independent predictor of thymoma recurrence after complete resection. Tumor size demonstrated a borderline association, suggesting a potential contributory role that requires further validation. MG, although clinically important for peri- and post-operative management, was not independently associated with recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.